Dose Ranging Study With LT, Monotherapy, PPAR

A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

NCT00162305 ·Status: COMPLETED ·Phase: PHASE2

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

NCT01240980 ·Status: COMPLETED ·Phase: PHASE1

Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

NCT01290575 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus

NCT00458016 ·Status: COMPLETED ·Phase: PHASE2

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

NCT01105429 ·Status: COMPLETED ·Phase: PHASE1

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

NCT00106808 ·Status: COMPLETED ·Phase: PHASE3

An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)

NCT00130806 ·Status: TERMINATED ·Phase: PHASE3

A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fed Conditions in Healthy Adult Volunteers

NCT06289933 ·Status: COMPLETED ·Phase: PHASE1

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

NCT00495469 ·Status: COMPLETED ·Phase: PHASE2

An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

NCT01022112 ·Status: COMPLETED ·Phase: PHASE2

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

NCT00263276 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes

NCT01282970 ·Status: COMPLETED ·Phase: PHASE1

Dose Ranging Study of Albiglutide in Japanese Subjects

NCT01098461 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)

NCT00790556 ·Status: COMPLETED ·Phase: PHASE1

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

NCT01498185 ·Status: COMPLETED ·Phase: PHASE2

To Evaluate 24-hr Glucose After OD vs BD AZD1656

NCT00819884 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00035984 ·Status: COMPLETED ·Phase: PHASE3

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

NCT00856908 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

NCT00924053 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

NCT01413204 ·Status: COMPLETED ·Phase: PHASE3

A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)

NCT01217073 ·Status: COMPLETED ·Phase: PHASE2

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

NCT02935712 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients

NCT00690287 ·Status: COMPLETED ·Phase: PHASE1

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

NCT00528372 ·Status: COMPLETED ·Phase: PHASE3

Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

NCT00500331 ·Status: COMPLETED ·Phase: PHASE2